Apr 13, 2023 7:30am EDT Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Mar 28, 2023 8:00am EDT Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Mar 20, 2023 4:01pm EDT Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
Mar 15, 2023 8:00am EDT Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
Mar 13, 2023 8:00am EDT Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
Mar 13, 2023 6:00am EDT Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
Mar 09, 2023 8:00am EST Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
Mar 08, 2023 8:00am EST Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
Mar 06, 2023 8:00am EST Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
